Trade Trade

Healthgen of Wuhan disputes USITC reliance on testing data, finding of domestic industry for Ventria Bioscience

By Melissa Ritti
  • 03 Sep 2024 18:33
  • 03 Sep 2024 18:33
The US International Trade Commission, Healthgen of Wuhan and Ventria Bioscience squared off today in oral arguments at the US Court of Appeals for the Federal Circuit.
At issue are allegations by Ventria that Healthgen makes plant-derived recombinant human serum albumins (rHSA) and rHSA-containing products that infringe claims 1 and

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

Latest News